CLINICAL_TRIALS
trial_result
· 2025-01-10
Clinical Trial Update: A Follow up Study to Protocol 101/2 - Continued Treatment by IPL344 IV [Phase 2]
Summary
The Phase 2 follow-up study of IPL344 IV for amyotrophic lateral sclerosis has been suspended.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Immunity Pharma Ltd. | Conditions: Amyotrophic Lateral Sclerosis (ALS) | Phase 2 | Status: SUSPENDED